Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

Resistance mutation analogs to nucleos(t)ides have been described in treatment-naïve patients with chronic hepatitis B (CHB), with clinical implications. The aim of this study was to investigate primary resistance mutations and genotypes circulating in patients naïve to chronic hepatitis B, in the N...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2017-01, Vol.10, p.201-207
Main Authors: Pacheco, Sidelcina Rugieri, Dos Santos, Maria Isabel Magalhães Andrade, Stocker, Andreas, Zarife, Maria Alice Sant'Anna, Schinoni, Maria Isabel, Paraná, Raymundo, Dos Reis, Mitermayer Galvão, Silva, Luciano Kalabric
Format: Article
Language:English
Subjects:
analogues nucleos(t)ides
Antigens
Care and treatment
Chronic Hepatitis B
Cirrhosis
Decision making
Deoxyribonucleic acid
Development and progression
Disease resistance
Distribution
DNA
DNA polymerase
Drug resistance
Epidemiology
Gastroenterology
Gene mutation
Genetic aspects
Genomes
Genotype & phenotype
Genotypes
Genotyping
Hepatitis
Hepatitis B
Hepatocellular carcinoma
Hepatology
Infections
Interferon
Laboratories
Liver
Liver cirrhosis
Microbial drug resistance
Mutation
Original Research
Patients
Physiological aspects
Polymerase chain reaction
Public health
resistance mutation
Systematic review
treatment-naïve
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Resistance mutation analogs to nucleos(t)ides have been described in treatment-naïve patients with chronic hepatitis B (CHB), with clinical implications. The aim of this study was to investigate primary resistance mutations and genotypes circulating in patients naïve to chronic hepatitis B, in the Northern and Northeastern regions of Brazil. We conducted a study of resistance mutations and genotypic characterization of hepatitis B virus (HBV) in 189 treatment-naïve patients chronically infected with HBV. Drug resistance-associated mutations located in the RT domain of the P gene (rtHBV) were found in 6% of the treatment-naïve patients from the Northeastern Region. The mutations were rtA194T, rtL180M + rtM204V, rtS202I, rtM204I, and rtA181S. No patient in the Northern Region had the resistance mutation. In the gene S region, the frequency of vaccine escape mutations was 2.4% in the Northeastern Region and 8.6% in the Northern Region. This information before the start of treatment may contribute to clinical decision making, reducing treatment failure and the risk of progression to cirrhosis and hepatocellular carcinoma for CHB.
ISSN:1178-6973
1178-6973
DOI:10.2147/IDR.S135420